Atopic dermatitis: crisaborole ointment boosts QoL for patients and caregivers

  • Simpson EL & al.
  • Dermatol Ther (Heidelb)
  • 22 Oct 2018

  • curated by Brian Richardson, PhD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results from phase 3 studies (AD-301/302) indicate that treatment with crisaborole ointment (Eucrisa) is associated with improved QoL in patients with mild-to-moderate atopic dermatitis (AD) and their parents/caregivers/families.

Why this matters

  • QoL is a major concern in treatment of AD.

Key results

  • In patients, crisaborole was associated with greater mean improvement in QoL compared with vehicle (−4.6 vs −3.0 [P<.001 in children dermatology life quality index for patients aged years vs>
  • Crisaborole was specifically linked with improvements in itching/scratching and painful/sore symptoms (P<.001 feelings of embarrassment and self-consciousness playing holiday time sleep burden treatment compared with vehicle.>
  • In parents/caregivers/family, crisaborole was associated with greater mean improvement in QoL compared with vehicle (−3.7 vs −2.7; P=.003 in Dermatitis Family Impact).

Study design

  • 1522 patients aged ≥2 years with mild-to-moderate AD, 1016 treated with crisaborole and 506 with vehicle, as well as families of patients aged 2-17 years, were analyzed for QoL.
  • Funding: Anacor Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., New York, NY.

Limitations

  • QoL measurement tools not specific to AD.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit